Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

Dr. Robert Holub, 41, left, recently joined the Alzheimer’s research practice of his father, Dr. Richard Holub, 77, ...

Patricia Clarkson, a three-time Emmy winner and Oscar nominee, stars as equal pay activist Lilly Ledbetter in the new movie, ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

There is increased use of quadruple medical therapy among patients following implementation of an HF quality improvement initiative.

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

News outlets break down the health effects rubber bullets and tear gas have on people, and how the use of such methods could open up governments to civil liability claims. Other states making news: ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...